[go: up one dir, main page]

WO1997022360A3 - Regulation de synthese de proteines et procede de criblage pour agents pharmaceutiques - Google Patents

Regulation de synthese de proteines et procede de criblage pour agents pharmaceutiques Download PDF

Info

Publication number
WO1997022360A3
WO1997022360A3 PCT/GB1996/003186 GB9603186W WO9722360A3 WO 1997022360 A3 WO1997022360 A3 WO 1997022360A3 GB 9603186 W GB9603186 W GB 9603186W WO 9722360 A3 WO9722360 A3 WO 9722360A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
control
protein synthesis
screening method
pkb
Prior art date
Application number
PCT/GB1996/003186
Other languages
English (en)
Other versions
WO1997022360A2 (fr
Inventor
Philip Cohen
Dario Alessi
Darren Cross
Original Assignee
Medical Res Council
Univ Dundee
Philip Cohen
Dario Alessi
Darren Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9526083.2A external-priority patent/GB9526083D0/en
Priority claimed from GBGB9610272.8A external-priority patent/GB9610272D0/en
Priority claimed from GBGB9615066.9A external-priority patent/GB9615066D0/en
Application filed by Medical Res Council, Univ Dundee, Philip Cohen, Dario Alessi, Darren Cross filed Critical Medical Res Council
Priority to JP09522599A priority Critical patent/JP2000502097A/ja
Priority to AU12004/97A priority patent/AU1200497A/en
Priority to EP96943208A priority patent/EP0868195A2/fr
Publication of WO1997022360A2 publication Critical patent/WO1997022360A2/fr
Publication of WO1997022360A3 publication Critical patent/WO1997022360A3/fr
Priority to US11/682,135 priority patent/US7897371B2/en
Priority to US13/021,048 priority patent/US20110275102A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Procédé de criblage d'agents capables d'affecter l'activité des kinases GSK3 et PKB, qui consiste à évaluer la phosphorylation de PKB sur deux acides aminés sur la molécule de PKB en particulier.
PCT/GB1996/003186 1995-11-16 1996-12-20 Regulation de synthese de proteines et procede de criblage pour agents pharmaceutiques WO1997022360A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP09522599A JP2000502097A (ja) 1995-12-20 1996-12-20 タンパク質合成の制御、および作用薬のスクリーニング法
AU12004/97A AU1200497A (en) 1995-12-20 1996-12-20 Control of protein synthesis, and screening method for agents
EP96943208A EP0868195A2 (fr) 1995-12-20 1996-12-20 Regulation de synthese de proteines et procede de criblage pour agents pharmaceutiques
US11/682,135 US7897371B2 (en) 1995-11-16 2007-03-05 Activation of mutated RAC-PK
US13/021,048 US20110275102A1 (en) 1995-11-16 2011-02-04 Activation of mutated rac-pk

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9526083.2 1995-12-20
GBGB9526083.2A GB9526083D0 (en) 1995-12-20 1995-12-20 Method
GB9610272.8 1996-05-16
GBGB9610272.8A GB9610272D0 (en) 1996-05-16 1996-05-16 Method
GB9615066.9 1996-07-18
GBGB9615066.9A GB9615066D0 (en) 1996-07-18 1996-07-18 Method

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09091763 A-371-Of-International 1998-06-19
US09/845,667 Continuation US20020065221A1 (en) 1995-11-16 2001-04-30 Control of protein synthesis, and screening method for agents

Publications (2)

Publication Number Publication Date
WO1997022360A2 WO1997022360A2 (fr) 1997-06-26
WO1997022360A3 true WO1997022360A3 (fr) 1997-07-31

Family

ID=27268041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/003186 WO1997022360A2 (fr) 1995-11-16 1996-12-20 Regulation de synthese de proteines et procede de criblage pour agents pharmaceutiques

Country Status (5)

Country Link
EP (1) EP0868195A2 (fr)
JP (1) JP2000502097A (fr)
AU (1) AU1200497A (fr)
CA (1) CA2241080A1 (fr)
WO (1) WO1997022360A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525702D0 (en) * 1995-12-15 1996-02-14 Ciba Geigy Ag Process for activating a kinase
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6682920B1 (en) 1997-09-26 2004-01-27 Onyx Pharmaceuticals, Inc. Compositions and methods for identifying PKB kinase inhibitors
JP2001518302A (ja) * 1997-09-26 2001-10-16 オニックス ファーマシューティカルズ，インコーポレイティド Ｐｋｂキナーゼインヒビターを同定するための組成物及び方法
SE9801530D0 (sv) * 1998-04-30 1998-04-30 Pharmacia & Upjohn Ab Method for screening
AU4669499A (en) * 1998-06-08 1999-12-30 Pharmacia & Upjohn Ab New therapeutic use of pkb (proteine kinase b) enhancers
EP1231934B1 (fr) * 1999-11-23 2004-03-24 Regeneron Pharmaceuticals, Inc. Methodes permettant d'inhiber l'atrophie ou de favoriser l'hypertrophie
CZ2003555A3 (en) 2000-07-27 2004-03-17 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
WO2002024941A2 (fr) * 2000-09-22 2002-03-28 University Of Dundee Regulation de proteine kinase
IL144583A0 (en) 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
EP1494675A4 (fr) 2002-04-08 2006-07-19 Merck & Co Inc Inhibiteurs de l'activite de akt
CA2480800C (fr) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibiteurs de l'activite akt
WO2003086403A1 (fr) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibiteurs de l'activite de akt
AU2003226271B2 (en) 2002-04-08 2007-10-18 Merck Sharp & Dohme Corp. Fused quinoxaline derivatives as inhibitors of Akt activity
GB0213614D0 (en) 2002-06-13 2002-07-24 Novartis Forschungsstiftlung Z Purified PKB Kinae and uses thereof
EP1558586B1 (fr) 2002-10-30 2011-03-30 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité de l'akt
US7414055B2 (en) 2003-04-24 2008-08-19 Merck & Co., Inc. Inhibitors of Akt activity
CN1809354A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
US7304063B2 (en) 2003-04-24 2007-12-04 Merck & Co., Inc. Inhibitors of Akt activity
US7638530B2 (en) 2003-04-24 2009-12-29 Merck & Co., Inc. Inhibitors of Akt activity
CN101389335A (zh) 2004-10-18 2009-03-18 安姆根有限公司 噻二唑化合物和使用方法
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
WO2009011871A2 (fr) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazoles modulateurs de l'activité de pkb
WO2009125798A1 (fr) * 2008-04-09 2009-10-15 萬有製薬株式会社 Procédé d'identification par criblage d'une substance pharmaceutique candidate pour le traitement du cancer par activation de la voie de signalisation hedgehog
EP3529615A1 (fr) 2016-10-24 2019-08-28 Novo Nordisk A/S Dosage biologique de formulations d'insuline

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
B. BURGERING ET AL.: "Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction.", NATURE, vol. 376, no. 6541, 17 August 1995 (1995-08-17), LONDON, GB, pages 599 - 602, XP002032104 *
D. ALESSI ET AL.: "Mechanism of activation of protein kinase B by insulin and IGF-1.", THE EMBO JOURNAL, vol. 15, no. 23, 2 December 1996 (1996-12-02), OXFORD, GB, pages 6541 - 6551, XP002032108 *
D. ALESSI ET AL.: "Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase.", FEBS LETTERS, vol. 399, no. 3, 16 December 1996 (1996-12-16), AMSTERDAM, NL, pages 333 - 338, XP002032109 *
D. CROSS ET AL.: "Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.", NATURE, vol. 378, no. 6559, 21 December 1995 (1995-12-21), LONDON, GB, pages 785 - 789, XP002025954 *
E. SIEGFRIED ET AL.: "Putative protein kinase product of the Drosophila segment-polarity gene zeste-white3.", NATURE, vol. 345, no. 6278, 28 June 1990 (1990-06-28), LONDON, GB, pages 825 - 829, XP002032106 *
H. KONISHI ET AL.: "Molecular cloning of rat RAC protein kinase alpha and beta and their association with protein kinase C gamma.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 205, no. 1, 30 November 1994 (1994-11-30), DULUTH, MN, USA, pages 817 - 825, XP002032107 *
T. FRANKE ET AL.: "The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase.", CELL, vol. 81, no. 5, 2 June 1995 (1995-06-02), CAMBRIDGE, MA, USA, pages 727 - 736, XP002032105 *

Also Published As

Publication number Publication date
CA2241080A1 (fr) 1997-06-26
JP2000502097A (ja) 2000-02-22
EP0868195A2 (fr) 1998-10-07
AU1200497A (en) 1997-07-14
WO1997022360A2 (fr) 1997-06-26

Similar Documents

Publication Publication Date Title
WO1997022360A3 (fr) Regulation de synthese de proteines et procede de criblage pour agents pharmaceutiques
SI0868125T1 (en) Adsorbent for phosphate from an aqueous medium, production and use of said adsorbent
AU5324996A (en) Protein kinase c inhibitors
AU1371999A (en) Benzothiazole protein tyrosine kinase inhibitors
AU7402196A (en) System and method for generating trusted, architecture specific, compiled versions of architecture neutral programs
AU2234695A (en) Rapid assays for protein kinase activity
AU7398194A (en) Oligonucleotide modulation of protein kinase c
AU7436494A (en) Protein isolate having an increased level of isoflavone compound and process for producing the same
AU8071698A (en) Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction
EP0864647B8 (fr) Oxydase de fructosylaminoacides, son procede d'obtention, et methode d'essai des composes d'amadori utilisant ladite oxydase
AU7247896A (en) Protein signature analysis
WO1999025843A3 (fr) Kinase humaine de controle, hcds1, compositions et procedes
AU7225396A (en) Method and system for determination of the pressure-volume relationship of the heart
EP1281770A3 (fr) Phosphodiesterase du cerveau humain et procédé de criblage
WO1998005786A3 (fr) Enzymes de transformation afc1 et rce1: caax isoprenyles
ZA985026B (en) Method for enhancing the activity of an enzyme.
AU6707396A (en) Processes for the production of amidase
AU1291097A (en) A novel protein kinase required for ras signal transduction
AU3524995A (en) Method for treatment of cancers by regulating the activity of ras proteins
AU6960296A (en) Methods and articles for enhanced protein adsorption and fluid management on surfaces
AU4630297A (en) Map kinases: polypeptides, polynucleotides and uses thereof
AU7936698A (en) Method for inferring protein functions with the use of ligand data base
AU9257998A (en) Method for enhancing the activity of an enzyme
AUPN720195A0 (en) Equine rhinovirus 1 proteins
AU2986395A (en) Method for screening compound libraries

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2241080

Country of ref document: CA

Ref country code: CA

Ref document number: 2241080

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1997 522599

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996943208

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996943208

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996943208

Country of ref document: EP